Search results for Enoblituzumab

Enoblituzumab Biosimilar – Anti-CD276, B7-H3 mAb – Research Grade, ProteoGenix, PX-TA1410

Description of Enoblituzumab Biosimilar - Anti-CD276, B7-H3 mAb - Research Grade General information on Anti-CD276/B7-H3[Homo sapiens] (Enoblituzumab) Monoclonal Antibody Enoblituzumab is investigated for the treatment of B7-H3-expressing Solid Tumors.

Enoblituzumab, Kyinno, KB-1331

Enoblituzumab, Abbexa, abx831368

Enoblituzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD276/B7-H3, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Enoblituzumab ELISA Kit, ProteoGenix, KPTX265

Description of Enoblituzumab ELISA Kit Introduction Enoblituzumab is a monoclonal antibody that has shown promising results in the treatment of various types of cancer. It specifically targets the immune checkpoint protein, programmed cell death protein 1 (PD-1), which is known to play a crucial role in suppressing the immune response against cancer cells. The detection and quantification of enoblituzumab in biological samples is essential for monitoring its therapeutic efficacy. This is where the Enoblituzumab ELISA Kit comes into play. Structure of Enoblituzumab Enoblituzumab is a humanized IgG1 monoclonal antibody, meaning that it is composed of human antibody sequences with a small portion of non-human sequences. It has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains are composed of constant and variable regions, while the light chains only have variable regions. The variable regions are responsible for binding to the target protein, PD-1. Activity of Enoblituzumab Enoblituzumab binds to PD-1 with high affinity and specificity, preventing its interaction with its ligands, PD-L1 and PD-L2. This interaction between PD-1 and its ligands is known to inhibit the function of T cells, which are responsible for killing cancer cells. By blocking this interaction, enoblituzumab enhances the anti-tumor immune response, leading to the destruction of cancer cells. Application of Enoblituzumab ELISA Kit The Enoblituzumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of enoblituzumab in biological samples, such as serum, plasma, and cell culture supernatants. This kit utilizes the sandwich ELISA technique, where the target protein is captured by a specific antibody coated on the surface of a microplate and then detected by a secondary antibody labeled with an enzyme. The enzyme catalyzes a colorimetric or chemiluminescent reaction, which can be measured using a spectrophotometer or luminometer, respectively. The Enoblituzumab ELISA Kit has a wide dynamic range, allowing for the accurate measurement of enoblituzumab at different concentrations. It also has a low limit of detection, making it suitable for monitoring the levels of enoblituzumab in patients receiving treatment. This kit is user-friendly, with a simple and fast protocol, and can be used in most laboratory settings. Conclusion Enoblituzumab is a promising therapeutic antibody that targets PD-1 and enhances the anti-tumor immune response. The Enoblituzumab ELISA Kit is an essential tool for the detection and quantification of enoblituzumab in biological samples, allowing for the monitoring of its therapeutic efficacy. With its high sensitivity, specificity, and user-friendly protocol, this kit is a valuable asset in the development and clinical use of enoblituzumab as a cancer treatment.

Enoblituzumab ELISA Kit, Abbexa, abx395154

Enoblituzumab ELISA Kit is a quantitative ELISA kit for detection of Enoblituzumab.Enoblituzumab (also referred to as MGA271) is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of the B7 family. This drug was developed by MacroGenics, Inc. that can be potentially used in the treatment of Solid tumors. Enoblituzumab is Fc-engineered with 5 amino acid substitutions to enhance binding to the activating FcγR and decrease binding to the inhibitory FcγR. Pre-clinical studies show that, in human CD16A-bearing transgenic mice, MGA271 exhibited potent antitumor activity in B7-H3–expressing xenograft models of renal cell and bladder carcinoma. To date, approximately 180 patients have received enoblituzumab monotherapy in a phase I study, with good tolerability. To determine the anti-tumor, immunological and biological effects of B7-H3 inhibition in high-risk localized pancreatic cancer, MacroGenics is currently conducting a neoadjuvant and pharmacodynamic phase II study.

Enoblituzumab Biosimilar - Research Grade, ichor.bio, ICH5124

Detects human CD276

Research Grade Enoblituzumab (HV612016), abinScience, HV612016